Meeting
2018 ASCO Annual Meeting
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – the RAMIRIS Study.
Authors
Sylvie Lorenzen
Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Sylvie Lorenzen , Peter C. Thuss-Patience , Claudia Pauligk , Eray Goekkurt , Thomas Jens Ettrich , Florian Lordick , Peter Reichardt , Michael Stahl , Hans-Georg Kopp , Susanna Hegewisch-Becker , Alexander Reichart , Hana Alguel , Dmitry Bichev , Angelika Kestler , Ulrich Hacker , Nicolas Stephan Ziegenhagen , Christian Mueller , Barbara Hermes , Salah-Eddin Al-Batran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03081143
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4132)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4132
Abstract #
TPS4132
Poster Bd #
320b
Abstract Disclosures
Similar Posters
First Author: Sylvie Lorenzen
Poster
2020 ASCO Virtual Scientific Program
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
First Author: Sylvie Lorenzen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922.
First Author: Michael J. Overman